Press Release Rachel Swansburg 11/10/25 Press Release Rachel Swansburg 11/10/25 City Therapeutics Announces Submission of Clinical Trial Application for CITY-FXI, an Investigational RNAi Therapeutic for the Treatment of Thromboembolic Diseases Read More News Rachel Swansburg 5/27/25 News Rachel Swansburg 5/27/25 Biogen taps City Therapeutics in RNAi deal worth up to $1B Read More Press Release Rachel Swansburg 5/27/25 Press Release Rachel Swansburg 5/27/25 Biogen and City Therapeutics Announce Strategic Research Collaboration to Develop Select Novel RNAi-based Therapies Read More Press Release Rachel Swansburg 4/17/25 Press Release Rachel Swansburg 4/17/25 City Therapeutics Expands Executive Team and Board of Directors Read More News Rachel Swansburg 2/11/25 News Rachel Swansburg 2/11/25 John Maraganore shares his take on biotech in 2025 and discusses the science behind his recently launched RNAi company, City Therapeutics Read More News Rachel Swansburg 1/10/25 News Rachel Swansburg 1/10/25 Bausch + Lomb pens $485M-plus biobucks pact with City Tx for RNAi eye disease work Read More Press Release IT Admin 1/10/25 Press Release IT Admin 1/10/25 City Therapeutics Announces Strategic Collaboration with Bausch + Lomb to Develop a Novel RNAi-Based Treatment for Geographic Atrophy Read More Press Release IT Admin 1/7/25 Press Release IT Admin 1/7/25 City Therapeutics Appoints Andy Orth as Chief Executive Officer Read More News Rachel Swansburg 10/10/24 News Rachel Swansburg 10/10/24 Crypto for CRISPR, a new RNAi startup, & a Nobel for AI Read More News Rachel Swansburg 10/8/24 News Rachel Swansburg 10/8/24 Startup led by John Maraganore raises $135M to build ‘future of RNAi’ Read More News Rachel Swansburg 10/8/24 News Rachel Swansburg 10/8/24 City Therapeutics breaks ground with $135M and blueprints from RNAi expert John Maraganore Read More News Matthew Zola 10/8/24 News Matthew Zola 10/8/24 Biotech veteran John Maraganore raises $135 million for his ‘next-generation RNAi’ startup Read More Press Release Matthew Zola 10/8/24 Press Release Matthew Zola 10/8/24 City Therapeutics Launches with $135 Million Series A Financing to Lead the Future of RNAi-based Medicine Read More
Press Release Rachel Swansburg 11/10/25 Press Release Rachel Swansburg 11/10/25 City Therapeutics Announces Submission of Clinical Trial Application for CITY-FXI, an Investigational RNAi Therapeutic for the Treatment of Thromboembolic Diseases Read More
News Rachel Swansburg 5/27/25 News Rachel Swansburg 5/27/25 Biogen taps City Therapeutics in RNAi deal worth up to $1B Read More
Press Release Rachel Swansburg 5/27/25 Press Release Rachel Swansburg 5/27/25 Biogen and City Therapeutics Announce Strategic Research Collaboration to Develop Select Novel RNAi-based Therapies Read More
Press Release Rachel Swansburg 4/17/25 Press Release Rachel Swansburg 4/17/25 City Therapeutics Expands Executive Team and Board of Directors Read More
News Rachel Swansburg 2/11/25 News Rachel Swansburg 2/11/25 John Maraganore shares his take on biotech in 2025 and discusses the science behind his recently launched RNAi company, City Therapeutics Read More
News Rachel Swansburg 1/10/25 News Rachel Swansburg 1/10/25 Bausch + Lomb pens $485M-plus biobucks pact with City Tx for RNAi eye disease work Read More
Press Release IT Admin 1/10/25 Press Release IT Admin 1/10/25 City Therapeutics Announces Strategic Collaboration with Bausch + Lomb to Develop a Novel RNAi-Based Treatment for Geographic Atrophy Read More
Press Release IT Admin 1/7/25 Press Release IT Admin 1/7/25 City Therapeutics Appoints Andy Orth as Chief Executive Officer Read More
News Rachel Swansburg 10/10/24 News Rachel Swansburg 10/10/24 Crypto for CRISPR, a new RNAi startup, & a Nobel for AI Read More
News Rachel Swansburg 10/8/24 News Rachel Swansburg 10/8/24 Startup led by John Maraganore raises $135M to build ‘future of RNAi’ Read More
News Rachel Swansburg 10/8/24 News Rachel Swansburg 10/8/24 City Therapeutics breaks ground with $135M and blueprints from RNAi expert John Maraganore Read More
News Matthew Zola 10/8/24 News Matthew Zola 10/8/24 Biotech veteran John Maraganore raises $135 million for his ‘next-generation RNAi’ startup Read More
Press Release Matthew Zola 10/8/24 Press Release Matthew Zola 10/8/24 City Therapeutics Launches with $135 Million Series A Financing to Lead the Future of RNAi-based Medicine Read More
